Granted Patent
B2
US 11,185,583 · App. 15/117,354 · Granted Nov 30, 2021
Multi-functional mucosal vaccine platform
Assignees:
Albany Medical College; University of Washington through its Center for Commercialization
A61K39/385A61K39/0011A61K39/001106A61K39/001151A61K39/001156A61K39/001157A61K39/001164A61K39/001171A61K39/001184A61K39/001186A61K39/001188A61K39/001191A61K39/001192A61K39/001194A61K39/001197A61K39/02A61K39/092C07K14/195C07K14/3156C07K14/4748C07K14/765C07K16/283A61K2039/53A61K2039/543A61K2039/545A61K2039/575A61K2039/6056A61K2039/6081C07K2317/24C07K2317/35C07K2317/52C07K2317/55C07K2317/77C07K2319/03C07K2319/30C07K2319/31C07K2319/40
View Patent ↗
Loading inventors, assignments & file history…
Abstract
An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyR1-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.
Claims (3)
1. An immunogenic fusion protein for use as a mucosal vaccine,
wherein the immunogenic fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:13.
2. The immunogenic fusion protein of claim 1 , wherein the fusion protein enhances transepithelial transport of the fusion protein to the nasal-associated lymphoid tissue (NALT) and enhances FcγR1 crosslinking by the fusion protein on antigen presenting cells (APC) within the NALT.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2021
From: GOSSELIN, EDMUND J.
To: ALBANY MEDICAL COLLEGE
Reel/Frame 057892/0005 →
Continuity (2)
Provisional Application
61938607
· Feb 11, 2014